Manfred P. Wirth
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Manfred P. Wirth has a total of 29 co-authors. Here are the top co-authors by number of shared publications:
Michael Froehner
3 shared publicationsC Tyrrell
Plymouth Oncology Centre, Derriford Hospital, Plymouth, UK
2 shared publicationsD M A Wallace
Department of Urology, Queen Elizabeth Medical Centre, Edgbaston, Birmingham, UK
2 shared publicationsF Pina
Servico de Urologica, Hospital de São Joao, Porto, Portugal
2 shared publicationsJ Armstrong
2 shared publicationsJ Hetherington
Princess Royal Hospital, Hull, UK
2 shared publications
Latest Publications
- 14 November 2006
- Published by Springer Nature in Prostate Cancer and Prostatic Diseases
- Vol. 10 (1) , 87-93
Bicalutamide (Casodex) 150 mg plus standard care in early non-metastatic prostate cancer: results from Early Prostate Cancer Trial 24 at a median 7 years' follow-up
Trial 24, one of three ongoing trials in the Early Prostate Cancer programme, is evaluating the efficacy and tolerability of bicalutamide (Casodex) 150 mg following standard care (radiotherapy, radical prostatectomy or watchful waiting) in patients with early, non-metastatic prostate cancer. At 7 years' median follow-up, addition of bicalutamide significantly improved objective progression-free survival (PFS) for patients with locally advanced disease, reducing the risk of progression by 34% versus standard care alone (hazard ratio 0.66; 95% confidence interval 0.55, 0.79; P<0.001). In localized disease, a significant difference in objective PFS was not found. There was no significant difference in overall survival.Articl
- 14 November 2006
- Published by Springer Nature in Prostate Cancer and Prostatic Diseases
- Vol. 10 (1) , 87-93
Bicalutamide (Casodex) 150 mg plus standard care in early non-metastatic prostate cancer: results from Early Prostate Cancer Trial 24 at a median 7 years' follow-up
Trial 24, one of three ongoing trials in the Early Prostate Cancer programme, is evaluating the efficacy and tolerability of bicalutamide (Casodex) 150 mg following standard care (radiotherapy, radical prostatectomy or watchful waiting) in patients with early, non-metastatic prostate cancer. At 7 years' median follow-up, addition of bicalutamide significantly improved objective progression-free survival (PFS) for patients with locally advanced disease, reducing the risk of progression by 34% versus standard care alone (hazard ratio 0.66; 95% confidence interval 0.55, 0.79; P<0.001). In localized disease, a significant difference in objective PFS was not found. There was no significant difference in overall survival.Articl
- Open Access
- 1 June 2005
- Published by Springer Nature in Prostate Cancer and Prostatic Diseases
- Vol. 8 (2) , 194-200
Bicalutamide (‘Casodex’) 150 mg in addition to standard care in patients with nonmetastatic prostate cancer: updated results from a randomised double-blind phase III study (median follow-up 5.1 y) in the early prostate cancer programme
Trial 24 is one of three placebo-controlled trials within the ongoing bicalutamide (‘Casodex’†) Early Prostate Cancer (EPC) programme evaluating bicalutamide 150 mg/day in addition to radical prostatectomy, radiotherapy or watchful waiting for T1b–4, any N, M0 prostate cancer. In Trial 24, at 5.1 y median follow-up, the addition of bicalutamide significantly (PP=0.746). In the context of the whole EPC programme, long-term bicalutamide is not appropriate for localised disease, yet provides advantages in delaying disease progression in patients with locally advanced prostate cancer.
- 1 June 2005
- Published by Springer Nature in Prostate Cancer and Prostatic Diseases
- Vol. 8 (2) , 194-200
Open AccessBicalutamide (‘Casodex’) 150 mg in addition to standard care in patients with nonmetastatic prostate cancer: updated results from a randomised double-blind phase III study (median follow-up 5.1 y) in the early prostate cancer programme
Trial 24 is one of three placebo-controlled trials within the ongoing bicalutamide (‘Casodex’†) Early Prostate Cancer (EPC) programme evaluating bicalutamide 150 mg/day in addition to radical prostatectomy, radiotherapy or watchful waiting for T1b–4, any N, M0 prostate cancer. In Trial 24, at 5.1 y median follow-up, the addition of bicalutamide significantly (PP=0.746). In the context of the whole EPC programme, long-term bicalutamide is not appropriate for localised disease, yet provides advantages in delaying disease progression in patients with locally advanced prostate cancer.
- 1 May 2005
- Published by Wolters Kluwer Health in European Journal of Anaesthesiology
- Vol. 22 (Supplement) , 112
Implementing thoracic epidural analgesia for postoperative pain relief within a clinical pathway reduces the incidence and severity of early non-surgical complications in patients undergoing open radical prostatectomy
- 1 May 2005
- Published by Wolters Kluwer Health in European Journal of Anaesthesiology
- Vol. 22 (Supplement) , 112
Implementing thoracic epidural analgesia for postoperative pain relief within a clinical pathway reduces the incidence and severity of early non-surgical complications in patients undergoing open radical prostatectomy
- 1 September 2003
- Published by S. Karger AG in Oncology
- Vol. 65 (Suppl. 1) , 1-4
Adjuvant Hormonal Treatment for Prostate Cancer: The Bicalutamide Early Prostate Cancer Program
Adjuvant hormonal therapy has been demonstrated to be able to delay disease progression in nonmetastatic prostate cancer. To date, however, a favorable impact on survival has only been demonstrated in lymph-node-positive disease and in external-beam radiotherapy series with locally advanced and probably mainly micrometastatic tumors. The Bicalutamide Early Prostate Cancer Program is the largest study under way to define the role of adjuvant treatment in early prostate cancer and identify subgroups of patients likely to benefit from immediate hormonal therapy. At the time of the most recently published analysis, the risk of objective clinical progression was significantly reduced in the bicalutamide arm (hazards ratio 0.58, 95% confidence interval 0.51–0.66, p < 0.0001). However, further maturation of data is needed to see whether this difference will lead to a survival advantage.
- 1 September 2003
- Published by S. Karger AG in Oncology
- Vol. 65 (Suppl. 1) , 1-4
Adjuvant Hormonal Treatment for Prostate Cancer: The Bicalutamide Early Prostate Cancer Program
Adjuvant hormonal therapy has been demonstrated to be able to delay disease progression in nonmetastatic prostate cancer. To date, however, a favorable impact on survival has only been demonstrated in lymph-node-positive disease and in external-beam radiotherapy series with locally advanced and probably mainly micrometastatic tumors. The Bicalutamide Early Prostate Cancer Program is the largest study under way to define the role of adjuvant treatment in early prostate cancer and identify subgroups of patients likely to benefit from immediate hormonal therapy. At the time of the most recently published analysis, the risk of objective clinical progression was significantly reduced in the bicalutamide arm (hazards ratio 0.58, 95% confidence interval 0.51–0.66, p < 0.0001). However, further maturation of data is needed to see whether this difference will lead to a survival advantage.
- 1 January 2003
- Published by Springer Nature in Drugs & Aging
- Vol. 20 (2) , 115-124
Value of Endocrine Therapy for Early and Locally Advanced Prostate Cancer
Prostate-specific antigen-based screening and increased public awareness of prostate cancer have led to earlier detection of localised and potentially curable tumour stages. Nevertheless, disease...
- 1 January 2003
- Published by Springer Nature in Drugs & Aging
- Vol. 20 (2) , 115-124
Value of Endocrine Therapy for Early and Locally Advanced Prostate Cancer
Prostate-specific antigen-based screening and increased public awareness of prostate cancer have led to earlier detection of localised and potentially curable tumour stages. Nevertheless, disease...
- 31 October 2002
- Published by Elsevier in European Urology Supplements
- Vol. 1 (7) , 20-25
Immediate Therapy in Early Prostate Cancer: Results from the Bicalutamide (‘Casodex’) EPC Programme
- 31 October 2002
- Published by Elsevier in European Urology Supplements
- Vol. 1 (7) , 20-25
Immediate Therapy in Early Prostate Cancer: Results from the Bicalutamide (‘Casodex’) EPC Programme
- 1 January 2002
- Published by Springer Nature in American Journal of Cancer
- Vol. 1 (6) , 387-396
The Management of Localized or Locally Advanced Prostate Cancer
- 1 January 2002
- Published by Springer Nature in American Journal of Cancer
- Vol. 1 (6) , 387-396
The Management of Localized or Locally Advanced Prostate Cancer
- 1 April 2001
- Published by S. Karger AG in Oncology Research and Treatment
- Vol. 24 (2) , 139-142
Etiologic Factors in Soft Tissue Sarcomas
Soft tissue sarcomas account for about 1% of all malignancies. The increase in incidence of soft tissue sarcomas during the recent decades may predominantly be attributed to AIDS-related Kaposi’s sarcoma; when this tumor is excluded, conclusive evidence for an age-adjusted increase is lacking. Beside the well investigated role of the human immunodeficiency virus 1 (HIV-1) and the human herpesvirus 8 (HHV-8) in the tumorigenesis of AIDS-related Kaposi’s sarcoma and several inherited disorders, considerable evidence support a relationship between occupational chemicals as vinyl chloride, phenoxyacetic acid herbicides, chlorphenols, dioxin, medicinal measures as Thorotrast exposure and therapeutic irradiation, and the development of soft tissue sarcoma. Hormones and chronic repair processes are further probably sarcoma-promoting factors. Considering the rarity of soft tissue sarcomas despite the vast portion that soft tissues comprise in the human body, additional knowledge on the tumorigenesis of soft tissue sarcomas might considerably contribute to the understanding of the etiologic pathways of malignant tumors in humans.
- 1 April 2001
- Published by S. Karger AG in Oncology Research and Treatment
- Vol. 24 (2) , 139-142
Etiologic Factors in Soft Tissue Sarcomas
Soft tissue sarcomas account for about 1% of all malignancies. The increase in incidence of soft tissue sarcomas during the recent decades may predominantly be attributed to AIDS-related Kaposi’s sarcoma; when this tumor is excluded, conclusive evidence for an age-adjusted increase is lacking. Beside the well investigated role of the human immunodeficiency virus 1 (HIV-1) and the human herpesvirus 8 (HHV-8) in the tumorigenesis of AIDS-related Kaposi’s sarcoma and several inherited disorders, considerable evidence support a relationship between occupational chemicals as vinyl chloride, phenoxyacetic acid herbicides, chlorphenols, dioxin, medicinal measures as Thorotrast exposure and therapeutic irradiation, and the development of soft tissue sarcoma. Hormones and chronic repair processes are further probably sarcoma-promoting factors. Considering the rarity of soft tissue sarcomas despite the vast portion that soft tissues comprise in the human body, additional knowledge on the tumorigenesis of soft tissue sarcomas might considerably contribute to the understanding of the etiologic pathways of malignant tumors in humans.
- 1 March 2000
- Vol. 163 (3) , 894-5
Ossifying cavernous hemangioma masquerading as adrenal tuberculosis.
- 1 March 2000
- Vol. 163 (3) , 894-5
Ossifying cavernous hemangioma masquerading as adrenal tuberculosis.